You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 3.1% | 3.9% |
| Div Cover | 3.2 | 2.6 |
| Op Mrgn | 21.9% | 27.9% |
| ROCE | 61.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | 10.3 | 0.0 |
| PEG | 0.4 | 3.7 |
| Price / Revenue | 2.0 | 2.0 |
| Price / Book value | 5.8 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 17.4% | -21.6% |
| PBT | 56.4% | n/a |
| EPS | 23.4% | 14.9% |
| DPS | -56.0% | -1.4% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 30,821.00 | 4,800.00 | 119.40p | 15.6 | 2.3 | 7% | 80.00p | 4.3% |
| 2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
| 2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
| 2021-12-31 | 24,969.00 | 3,599.00 | 113.20p | 17.7 | -7.6 | -2% | 100.00p | 5.0% |
| 2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.4 | 23% | 44.00p | 3.1% |
| FDA approves GSK anaemia drug Sharecast News | 02 Feb |
|---|---|
| Record vaccine sales boost profits at GSK Sharecast News | 01 Feb |
| GSK plans return of HQ to central London in 2024 Sharecast News | 12 Dec |
| Daprodustat approved by US FDA for anaemia of CKD | 02-Feb-23 14:10 |
|---|---|
| Director/PDMR Shareholding | 01-Feb-23 23:58 |
| Total Voting Rights | 01-Feb-23 23:58 |
| Benlysta granted Orphan Drug Designation by US FDA | 01-Feb-23 14:57 |
| Final Results | 01-Feb-23 14:48 |